By Cait Kearney
Experts debated positron emission tomography (PET) as a suitable surrogate endpoint for clinically meaningful outcomes and accelerated approval of Alzheimer’s drugs at an event held by the Internal Ethics Committee of the Alzheimer’s Clinical Trials Consortium (ACTC).